Shire in the hunt for promising new stem cell tech

The UK's Shire has been making a series of small-$3 million to $5 million-investments in stem cell developers as the CEO continues to hunt for viable new business opportunities. "The science is there," said Angus Russell, "the challenge is finding something you can turn into a business." Russell makes clear that he's taking a distinctly unsentimental approach to stem cell research, noting that he only wants to acquire technology that insurers will be willing to pay for. Report

Suggested Articles

Panelists at the CAR-TCR Summit reflected on gender diversity trends and the challenges women face in the life sciences industry.

Loh joins the computational chemistry specialist after a two-year stint at Kymera Therapeutics.

The $3 billion funding boost includes an additional $350 million for targeted Alzheimer’s research.